152 filings
Page 5 of 8
8-K
4yuiwa9lv0 wzx1
4 Dec 18
Entry into a Material Definitive Agreement
8:14am
8-K
1y102j n2q
1 Nov 18
Revance Releases Third Quarter 2018 Results
4:10pm
8-K
erw tzmb0w
11 Oct 18
Departure of Directors or Certain Officers
8:53am
8-K
0qr7qfr
2 Aug 18
Results of Operations and Financial Condition
4:17pm
8-K
zy13y1
22 Jun 18
Departure of Directors or Certain Officers
4:12pm
8-K
eiel897aly
29 May 18
Departure of Directors or Certain Officers
9:37am
8-K
fe9oqsr
11 May 18
Entry into a Material Definitive Agreement
4:58pm
8-K
qus3s
8 May 18
Revance Releases First Quarter 2018 Results
4:14pm
8-K
jjf20wevsi
19 Apr 18
Revance Investor Day Highlights New Neuroscience Indications in Development
12:00am
8-K
pnwf1skbcvz 4bei
13 Mar 18
Entry into a Material Definitive Agreement
12:00am
8-K
h1tzdk
28 Feb 18
Revance Releases Fourth Quarter and Full Year 2017 Results
12:00am
8-K
ix6bk
28 Feb 18
Entry into a Material Definitive Agreement
12:00am
8-K
btun n3qlzi3lmblkt
9 Feb 18
Departure of Directors or Certain Officers
12:00am
8-K
0s61qooe7yccys4g
8 Jan 18
Revance Announces Interim Phase 2a Results for RT002 in Treating Plantar Fasciitis
12:00am
8-K
fyvwe121gc4l m0
4 Jan 18
Revance Provides Update on Anticipated Clinical Milestones and Financial Outlook for 2018
12:00am
8-K
5g6hq
7 Dec 17
Entry into a Material Definitive Agreement
12:00am
8-K
kkat6n0yadv
5 Dec 17
Achieves6-Month Duration in Pivotal SAKURA Phase 3 Trials for Glabellar Lines
12:00am
8-K
z6anjad3ew3tstnas7m
5 Dec 17
Other Events
12:00am
8-K
qrtz0ata0u
2 Nov 17
Revance Releases Third Quarter 2017 Results
12:00am
8-K
1xrp8n
6 Sep 17
Revance Appoints Mark Foley to its Board of Directors
12:00am